1. Home
  2. REVB vs NBY Comparison

REVB vs NBY Comparison

Compare REVB & NBY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REVB
  • NBY
  • Stock Information
  • Founded
  • REVB 2020
  • NBY 2000
  • Country
  • REVB United States
  • NBY United States
  • Employees
  • REVB N/A
  • NBY N/A
  • Industry
  • REVB Biotechnology: Pharmaceutical Preparations
  • NBY
  • Sector
  • REVB Health Care
  • NBY
  • Exchange
  • REVB Nasdaq
  • NBY Nasdaq
  • Market Cap
  • REVB 3.8M
  • NBY 3.8M
  • IPO Year
  • REVB N/A
  • NBY 2007
  • Fundamental
  • Price
  • REVB $2.38
  • NBY $0.63
  • Analyst Decision
  • REVB
  • NBY Strong Buy
  • Analyst Count
  • REVB 0
  • NBY 1
  • Target Price
  • REVB N/A
  • NBY $0.85
  • AVG Volume (30 Days)
  • REVB 283.8K
  • NBY 40.6K
  • Earning Date
  • REVB 08-08-2025
  • NBY 08-12-2025
  • Dividend Yield
  • REVB N/A
  • NBY N/A
  • EPS Growth
  • REVB N/A
  • NBY N/A
  • EPS
  • REVB N/A
  • NBY 0.57
  • Revenue
  • REVB N/A
  • NBY $9,781,000.00
  • Revenue This Year
  • REVB N/A
  • NBY $23.91
  • Revenue Next Year
  • REVB N/A
  • NBY $32.05
  • P/E Ratio
  • REVB N/A
  • NBY $1.41
  • Revenue Growth
  • REVB N/A
  • NBY 20.52
  • 52 Week Low
  • REVB $2.11
  • NBY $0.36
  • 52 Week High
  • REVB $168.00
  • NBY $1.01
  • Technical
  • Relative Strength Index (RSI)
  • REVB 34.09
  • NBY 48.53
  • Support Level
  • REVB $2.97
  • NBY $0.63
  • Resistance Level
  • REVB $3.18
  • NBY $0.68
  • Average True Range (ATR)
  • REVB 0.22
  • NBY 0.05
  • MACD
  • REVB 0.05
  • NBY -0.00
  • Stochastic Oscillator
  • REVB 7.14
  • NBY 15.71

About REVB Revelation Biosciences Inc.

Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

About NBY NovaBay Pharmaceuticals Inc.

NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.

Share on Social Networks: